TY - JOUR
T1 - Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va
AU - Deguchi, Hiroshi
AU - Sinha, Ranjeet K.
AU - Marchese, Patrizia
AU - Ruggeri, Zaverio M.
AU - Zilberman-Rudenko, Jevgenia
AU - McCarty, Owen J.T.
AU - Cohen, Mitchell J.
AU - Griffin, John H.
N1 - Funding Information:
This work was supported, in part, by National Institutes of Health, National Heart, Lung, and Blood Institute grants RO1 HL021544, RO1 HL052246, and PO1 HL031950 (J.H.G.); National Center for Advancing Translational Sciences grant 8UL1 TR000109 (Clinical and Translational Science Award, principal investigator: Eric Topol); National Heart, Lung, and Blood Institute grant UO1 HL077863 and Department of Defense grant W81XWH-10-1-0509 (M.J.C.); National Heart, Lung, and Blood Institute grants PO1 HL031950 and RO1 HL117722 (Z.M.R.); and National Heart, Lung, and Blood Institute grant R01HL101972 and National Institute of General Medical Sciences grant R01GM116184 (O.J.T.M); and by a grant from the Stein Endowment Fund (courtesy of J. W. Kelly, Scripps Research Institute).
Funding Information:
This work was supported, in part, by National Institutes of Health, National Heart, Lung, and Blood Institute grants RO1HL021544,RO1 HL052246, and PO1HL031950 (J.H.G.);National Center for Advancing Translational Sciences grant 8UL1TR000109 (Clinical and Translational Science Award, principal investigator:EricTopol); National Heart, Lung, and Blood Institute grant UO1 HL077863 and Department of Defense grant W81XWH-10-1-0509 (M.J.C.); National Heart, Lung, and Blood Institute grants PO1 HL031950 and RO1 HL117722 (Z.M.R.); and National Heart, Lung, and Blood Institute grant R01HL101972 and National Institute of General Medical Sciences grant R01GM116184 (O.J.T.M); and by a grant fromthe Stein Endowment Fund (courtesy of J. W. Kelly, Scripps Research Institute).
Publisher Copyright:
© 2016 by The American Society of Hematology.
PY - 2016
Y1 - 2016
N2 - To test the hypothesis that skeletal muscle myosins can directly influence blood coagulation and thrombosis, ex vivo studies of the effects of myosin on thrombogenesis in fresh human blood were conducted. Addition of myosin to blood augmented the thrombotic responses of human blood flowing over collagen-coated surfaces (300 s-1 shear rate). Perfusion of human blood over myosin-coated surfaces also caused fibrin and platelet deposition, evidencing myosin's thrombogenicity. Myosin markedly enhanced thrombin generation in both platelet-rich plasma and platelet-poor plasma, indicating that myosin promoted thrombin generation in plasma primarily independent of platelets. In purified reaction mixtures composed only of factor Xa, factor Va, prothrombin, and calcium ions, myosin greatly enhanced prothrombinase activity. The Gla domain of factor Xa was not required for myosin's prothrombinase enhancement. When binding of purified clotting factors to immobilizedmyosin wasmonitored using biolayer interferometry, factors Xa and Va each showed favorable binding interactions. Factor Va reduced by 100-fold the apparent Kd of myosin for factor Xa (Kd ~0.48 nM), primarily by reducing koff, indicating formation of a stable ternary complex of myosin:Xa:Va. In studies to assess possible clinical relevance for this discovery, we found that antimyosin antibodies inhibited thrombin generation in acute trauma patient plasmas more than in control plasmas (P = .0004), implying myosin might contribute to acute trauma coagulopathy. Weposit that myosin enhancement of thrombin generation could contribute either to promote hemostasis or to augment thrombosis risk with consequent implications for myosin's possible contributions to pathophysiology in the setting of acute injuries.
AB - To test the hypothesis that skeletal muscle myosins can directly influence blood coagulation and thrombosis, ex vivo studies of the effects of myosin on thrombogenesis in fresh human blood were conducted. Addition of myosin to blood augmented the thrombotic responses of human blood flowing over collagen-coated surfaces (300 s-1 shear rate). Perfusion of human blood over myosin-coated surfaces also caused fibrin and platelet deposition, evidencing myosin's thrombogenicity. Myosin markedly enhanced thrombin generation in both platelet-rich plasma and platelet-poor plasma, indicating that myosin promoted thrombin generation in plasma primarily independent of platelets. In purified reaction mixtures composed only of factor Xa, factor Va, prothrombin, and calcium ions, myosin greatly enhanced prothrombinase activity. The Gla domain of factor Xa was not required for myosin's prothrombinase enhancement. When binding of purified clotting factors to immobilizedmyosin wasmonitored using biolayer interferometry, factors Xa and Va each showed favorable binding interactions. Factor Va reduced by 100-fold the apparent Kd of myosin for factor Xa (Kd ~0.48 nM), primarily by reducing koff, indicating formation of a stable ternary complex of myosin:Xa:Va. In studies to assess possible clinical relevance for this discovery, we found that antimyosin antibodies inhibited thrombin generation in acute trauma patient plasmas more than in control plasmas (P = .0004), implying myosin might contribute to acute trauma coagulopathy. Weposit that myosin enhancement of thrombin generation could contribute either to promote hemostasis or to augment thrombosis risk with consequent implications for myosin's possible contributions to pathophysiology in the setting of acute injuries.
UR - http://www.scopus.com/inward/record.url?scp=84990213632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84990213632&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-03-707679
DO - 10.1182/blood-2016-03-707679
M3 - Article
C2 - 27421960
AN - SCOPUS:84990213632
SN - 0006-4971
VL - 128
SP - 1870
EP - 1878
JO - Blood
JF - Blood
IS - 14
ER -